冠心病心绞痛患者血浆MCP-1和MMP-9变化及其临床意义

Alteration and Clinical Significance of Plasma Monocyte Chemotactic Factor-1 and Matrix Metalloproteinase-9 in Patients with Angina Pectoris

目的探讨单核细胞趋化因子-1(MCP-1)及基质金属蛋白酶-9(MMP-9)在冠心病心绞痛发病机制中的作用。方法选择2011年5月—11月在我院心血管病研究所住院并经冠状动脉造影确诊的心绞痛65例,根据病情分为稳定型心绞痛(SAP)组32例,不稳定型心绞痛(UAP)组33例,同时选择同期30例冠状动脉造影正常者作为对照组。分别采用免疫浊度法和酶联免疫吸附法检测3组的血浆MCP-1、MMP-9水平,并进行对比分析。结果 UAP组血浆MCP-1、MMP-9平均为(18.95±3.62)pg/L、(23.19±4.65)mg/L,显著高于SAP组的(15.83±3.57)pg/L和(19.75±4.39)mg/L(P<0.01);且两组MCP-1、MMP-9均明显高于对照组的(11.53±3.45)pg/L、(16.31±4.23)mg/L(P<0.01)。结论冠状动脉粥样硬化作为一种炎症性疾病,血浆MCP-1和MMP-9等炎症介质对预测冠心病心绞痛的存在和发展有重要临床意义。

Objective To explore the role of monocyte chemotactic factor-1 （MCP-1） and matrix metalloproteinase-9 （MMP-9） in nosogenesis of patients with angina pectoris （AP）. Methods A total of 65 patients with AP diagnosed by coronary angiography in our institution of cardiovascular diseases from May to November 2011 were divided into stable angina pectoris group （SAP group, n =32） and unstable angina pectoris group （UAP group, n =33）, and 30 patients with normal coronary angiography were selected as control group. The level of MCP-1 and MMP-9 of 3 groups were measured and compared by immune nephelometry and enzyme linked immunosorbent assay （ELISA）. Results The average plasma levels of MCP-1 of （18.95 ± 3.62） pg/L and MMP-9 of （23.19 ＋4.65） mg/L in UAP group were significantly higher than those of （15.83 ±3.57） pg/L and （19.75±4.39） mg/L respectively in SAP group （P 〈0. 01）; and the average plasma levels of MCP-1 and MMP-9 in UAP and SAP were significantly higher than those of （11.53 ±3.45） pg/L and （16.31±4.23） mg/L respectively in control group （P 〈0.01）. Conclusion Coro- nary atherosclcrosis is an inflammatory disease, MCP-1 and MMP-9 are significant in predicting occurrence and development of angi- na peetoris. [